505 related articles for article (PubMed ID: 28849538)
1. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Grimm SE; Strong M; Brennan A; Wailoo AJ
Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
[TBL] [Abstract][Full Text] [Related]
2. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
3. Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries.
Efthymiadou O
Eur J Health Econ; 2023 Sep; 24(7):1023-1031. PubMed ID: 36219363
[TBL] [Abstract][Full Text] [Related]
4. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
5. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
6. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
Efthymiadou O; Kanavos P
Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
[TBL] [Abstract][Full Text] [Related]
7. A Conceptual Framework for Life-Cycle Health Technology Assessment.
Kirwin E; Round J; Bond K; McCabe C
Value Health; 2022 Jul; 25(7):1116-1123. PubMed ID: 35779939
[TBL] [Abstract][Full Text] [Related]
8. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
9. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
11. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
12. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
Pericleous L; Amin M; Goeree R
J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
[TBL] [Abstract][Full Text] [Related]
13. Health technology assessment and primary data collection for reducing uncertainty in decision making.
Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
[TBL] [Abstract][Full Text] [Related]
14. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
15. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
Schaefer R; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
[No Abstract] [Full Text] [Related]
16. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
[TBL] [Abstract][Full Text] [Related]
17. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
Robinson MF; Mihalopoulos C; Merlin T; Roughead E
Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
[TBL] [Abstract][Full Text] [Related]
18. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
19. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
Oortwijn W; Mathijssen J; Banta D
Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
[TBL] [Abstract][Full Text] [Related]
20. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
Thokala P; Carlson JJ; Drummond M
J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
